Core Viewpoint - Jinbo Biological has emerged as a significant player in the Shanxi capital market, being the highest-priced and highest-valued stock on the Beijing Stock Exchange, symbolizing the province's industrial transformation [1] Group 1: Company Overview - Jinbo Biological specializes in various terminal medical devices and functional skincare products, with A-type recombinant humanized collagen as its core material [2] - The company’s recombinant type III humanized collagen freeze-dried fibers received approval from the National Medical Products Administration in June 2021, marking it as the first medical device in China made from this innovative biomaterial [2] Group 2: Financial Performance - In the 2024 performance report, Jinbo Biological achieved a revenue of 1.447 billion yuan, representing a year-on-year growth of 85.40%, and a net profit of 733 million yuan, up 144.65% year-on-year [3] - Over four years, the company's revenue has increased more than fivefold, while net profit has nearly increased twelvefold compared to 2021 [3] Group 3: Strategic Focus - The company aims to focus on scientific innovation rather than competing in saturated markets, emphasizing the creation of new products and applications [3] - Jinbo Biological is committed to enhancing its brand presence both domestically and internationally, with plans to strengthen brand development in the coming year [7][8] Group 4: Talent Development - The company employs a "mentorship" approach for internal talent development, sending employees to prestigious research institutions for training [6] - Jinbo Biological is building a collaborative framework with academic and research institutions to continuously infuse new talent into the company [6] Group 5: Industry Context - Shanxi is undergoing a high-quality transformation, actively promoting emerging industries such as biomedicine, which supports the rapid rise of Jinbo Biological and the humanized collagen industry [4] - The biomedicine sector's reliance on high-end talent presents challenges for Jinbo Biological in attracting intellectual resources in Shanxi compared to larger cities [5]
对话新晋商｜锦波生物董事长杨霞：合成生物领域竞争激烈，选择走“从无到有”的赛道